Search

Author/Creator Hovingh, G Kees

1. A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. (April 2016)

Authors:
Leusink, Maarten; Maitland-van der Zee, Anke H; Ding, Bo; Drenos, Fotios; van Iperen, Erik PA; Warren, Helen R; Caulfield, Mark J; Cupples, L Adrienne; Cushman, Mary; Hingorani, Aroon D; Hoogeveen, Ron C; Hovingh, G Kees; Kumari, Meena; Lange, Leslie A; Munroe, Patricia B; Nyberg, Fredrik; Schrei...
Journal:
Pharmacogenomics
Issue:
Volume 17:Number 6(2016)
Page Start:
583
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Issue 9983 (30th May 2015)

Authors:
Kastelein, John J P; Besseling, Joost; Shah, Sukrut; Bergeron, Jean; Langslet, Gisle; Hovingh, G Kees; Al-Saady, Naab; Koeijvoets, Michiel; Hunter, John; Johnson-Levonas, Amy O; Fable, Jennifer; Sapre, Aditi; Mitchel, Yale
Journal:
Lancet
Issue:
Volume 385:Issue 9983(2015)
Page Start:
2153
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Characteristics of Patients in the 10th and 90th Percentile of LDL-C Reductions with Alirocumab: ODYSSEY Pooled Analyses. (June 2018)

Authors:
Rosenson, Robert S.; Roth, Eli M.; Ray, Kausik K.; Hovingh, G Kees; Bays, Harold E.; Laufs, Ulrich; Rader, Daniel J.; Baccara-Dinet, Marie T.; Thompson, Desmond; Louie, Michael J.; Leiter, Lawrence A.
Journal:
Atherosclerosis
Issue:
Volume 32(2018)
Page Start:
12
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Issue 9992 (1st August 2015)

Authors:
Hovingh, G Kees; Kastelein, John J P; van Deventer, Sander J H; Round, Patrick; Ford, John; Saleheen, Danish; Rader, Daniel J; Brewer, H Bryan; Barter, Philip J
Journal:
Lancet
Issue:
Volume 386:Issue 9992(2015)
Page Start:
452
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Issue 10 (October 2016)

Authors:
Santos, Raul D; Gidding, Samuel S; Hegele, Robert A; Cuchel, Marina A; Barter, Philip J; Watts, Gerald F; Baum, Seth J; Catapano, Alberico L; Chapman, M John; Defesche, Joep C; Folco, Emanuela; Freiberger, Tomas; Genest, Jacques; Hovingh, G Kees; Harada-Shiba, Mariko; Humphries, Steve E; Jackson,...
Journal:
Lancet
Issue:
Volume 4:Issue 10(2016)
Page Start:
850
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. (28th August 2020)

Authors:
Ray, Kausik K; Molemans, Bart; Schoonen, W Marieke; Giovas, Periklis; Bray, Sarah; Kiru, Gaia; Murphy, Jennifer; Banach, Maciej; De Servi, Stefano; Gaita, Dan; Gouni-Berthold, Ioanna; Hovingh, G Kees; Jozwiak, Jacek J; Jukema, J Wouter; Kiss, Robert Gabor; Kownator, Serge; Iversen, Helle K; Maher...
Journal:
European journal of preventive cardiology
Issue:
Volume 28:Number 11(2021)
Page Start:
1279
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Issue 10289 (29th May 2021)

Authors:
Ridker, Paul M; Devalaraja, Matt; Baeres, Florian M M; Engelmann, Mads D M; Hovingh, G Kees; Ivkovic, Milana; Lo, Larry; Kling, Douglas; Pergola, Pablo; Raj, Dominic; Libby, Peter; Davidson, Michael
Journal:
Lancet
Issue:
Volume 397:Issue 10289(2021)
Page Start:
2060
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Issue 9965 (24th January 2015)

Authors:
Raal, Frederick J; Honarpour, Narimon; Blom, Dirk J; Hovingh, G Kees; Xu, Feng; Scott, Rob; Wasserman, Scott M; Stein, Evan A
Journal:
Lancet
Issue:
Volume 385:Issue 9965(2015)
Page Start:
341
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Issue 4 (April 2017)

Authors:
Raal, Frederick J; Hovingh, G Kees; Blom, Dirk; Santos, Raul D; Harada-Shiba, Mariko; Bruckert, Eric; Couture, Patrick; Soran, Handrean; Watts, Gerald F; Kurtz, Christopher; Honarpour, Narimon; Tang, Lihua; Kasichayanula, Sree; Wasserman, Scott M; Stein, Evan A
Journal:
Lancet
Issue:
Volume 5:Issue 4(2017)
Page Start:
280
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗